Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 10:27 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10492
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Active, not recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 25–36 of 10,492 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

NCT00039676
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Hodgkin Disease, NonHodgkin Lymphoma, Mixed Lymphoproliferative Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
11 Months and older
Enrollment
1,836 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer

NCT05868486
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Genetic Testing for Cancer Risk, Liquid Biopsy, Magnetic Resonance Imaging of the Whole Body without Contrast, Survey Administration
Procedure · Genetic · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Not applicable Interventional

14022 ATTUNE Cementless RP Clinical Performance Evaluation

NCT02839850
View directory record Official record
Conditions
Osteoarthritis
Interventions
Cementless Total Knee Arthroplasty
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
22 Years to 80 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
10
States / cities
Denver, Colorado • DeLand, Florida • Lebanon, New Hampshire + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Not applicable Interventional

Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes

NCT05854069
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
FAMS-T1D, Digital resources for diabetes
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 24 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Approved Contact Lenses (CR-6657)

NCT07819305
View directory record Official record
Conditions
Visual Acuity
Interventions
Test (Senofilcon A), Control (Serafilcon A)
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
8
States / cities
Jacksonville, Florida • Franklin Park, Illinois • Camden, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02669251
View directory record Official record
Conditions
Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease, Bronchiolitis Obliterans Syndrome
Interventions
MPH966
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

NCT06903338
View directory record Official record
Conditions
Viral Hepatitis
Interventions
Tobevibart, Elebsiran
Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
13
States / cities
Chandler, Arizona • Los Angeles, California • Redwood City, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Phase 3 Interventional

A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses

NCT06851507
View directory record Official record
Conditions
Multiple Actinic Keratoses
Interventions
Fluorouracil 5-FU, Fluorouracil/Calcipotriene
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Phase 2 Interventional Results available

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

NCT04200443
View directory record Official record
Conditions
Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma, Unresectable Soft Tissue Sarcoma
Interventions
Cabozantinib, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Duarte, California • Chicago, Illinois • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Phase 2 Interventional

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

NCT02171104
View directory record Official record
Conditions
Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
Interventions
Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D)
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Phase 3 Interventional

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older · Female only
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
72
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Phase 2 Interventional

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

NCT04133636
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
33
States / cities
San Diego, California • San Francisco, California • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 10:27 AM EST